Malignant melanoma is one of the most rapidly increasing cancer types, and patients with metastatic disease have a very poor prognosis. Detection of metastatic melanoma cells in circulation may aid the clinician in assessing tumor progression, metastatic potential, and response to therapy. Tyrosinase is a key enzyme in melanine biosynthesis. The gene is actively expressed in melanocytes and melanoma cells. Melan A is a differentiation antigen that is expressed in melanocytes. The presence of these molecules in blood is considered a marker for circulating melanoma cells. In this study, we analyzed the usefulness of this marker combination in evaluating the response to therapy in the blood of 30 patients with malignant melanoma. Circulating cells were detected by a reverse-transcriptasepolymerase-chain reaction. The tyrosinase expression was observed in 9 (30%) patients and Melan A in 19 (63.3%) patients before therapy. Following treatment, the tyrosinase mRNA was detected in only one patient, while Melan A transcripts were still present in 14 patients. We suggest that this molecular assay can identify circulating melanoma cells that express melanoma-associated antigens and may provide an early indication of therapy effectiveness.
Introduction
Malignant melanoma is one of the fastest growing cancer forms with an annual increase of about 5% (Mellado et al., 1996; Proebstle et al., 2000) . Patients with metastatic disease have a very poor prognosis, with a 2-year survival rate of less than 5% (Evans and Manson, 1994) . In general, malignant melanoma metastasizes via the lymphatics and blood. Unfortunately, the metastatic risk cannot be estimated early enough by routine diagnostic and imaging methods. The presence of melanoma cells in circulation seems to be positively correlated with the rapid progress of the disease (Shivers et al., 2001) . Therefore, the detection of occult tumor cells in blood may permit a more accurate assessment of the prognosis and have important therapeutic implications (Foss et al., 1995) .
Tyrosinase is a key enzyme in melanin biosynthesis. The gene codes for a 529 amino acid membrane-bound glycoprotein, and it is only actively expressed in melanocytes (Hoon et al., 1995; Lipton et al., 1997) . The polymerase chain reaction-based detection of the tyrosinase messenger RNA in peripheral blood permits the detection of small numbers of circulating tumor cells. It has been reported that PCRpositivity during the early melanoma stages may indicate an increased risk for the development of hematogenous metastases (Mellado et al., 1996; Johansson et al., 2000) .
Other genes, such as gp100 (Adema et al., 1994) or MUC18 and p97 (Curry et al., 1998) , have also been reported to be expressed in cells of melanocytic origin. However, recent evidence suggests that these proteins are not specific to melanocytic cells, but can also be found in many different cell types (Brouwenstijn et al., 1997; Pickl et al., 1997; Curry et al., 1998) . Therefore, these molecules are unsuitable for investigating melanoma cells in peripheral blood.
Another candidate as a marker is Melan A, the Melanoma Antigen that is recognized by the T-cells 1 (MART-1). The gene codes for a 118 amino acid melanocyte-lineage differentiation antigen that is only expressed in melanocytes, melanocytic cells, and in the retina (Coulie et al., 1994; Chen et al., 1996) . The protein is recognized by melanoma-reactive CD8 cytotoxic T-cells (Zarour et al., 2000) , and a peptide that is derived from the protein binds to the class I major histocompatibility complex HLA A2 molecule (Ouesnel et al., 2001) . Most melanoma tumors and cell lines express this protein. However, its expression is not detected in other tissues and tumors (Goydos et al., 1998; Schittek et al., 1999) .
The detection of circulating melanoma cells in peripheral blood may help in the initial diagnosis and staging by allowing the detection of subclinical metastases. It may also improve our ability to monitor the spreading of metastatic disease and provide a means to study the effects of systemic therapy on circulating tumor cells (Taback et al., 2001; Blaheta et al., 1998) . Although multiple-marker analyses are more accurate than single-assay studies, combining different molecular parameters are rare, and the association between the detection of tumor cells and assessment of responsiveness to therapy and outcome has not been addressed adequately. In this study, we employed a sensitive two-marker RT-PCR assay to investigate the presence of tyrosinase and Melan A mRNAs in the peripheral blood of patients with malignant melanoma before and after therapy, in order to assess their utility in terms of treatment and prognosis. , for 3 days with 3 week intervals, when solid organ involvement was present.
Materials and Methods
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The median follow-up interval after blood sampling was 17 months (range 11-31 months; mean, 17.9 ± 5.4 months) for the patients. For the PCR analysis of the tyrosinase transcripts, two sets of primers were used from published sequences (Smith et al., 1991) ;
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These primer pairs yielded products of 284 bp and 207 bp, respectively.
For the analysis of Melan A, the primers were as follows;
The final products were electrophoresed on a 2% agarose gel, and evaluated using a gel documentation system (Vilber Lourmat, Marne-La-Vallee, France) after ethidium bromide staining. Positive RT-PCR results were repeated twice in order to confirm the results. The detection limit of our assay for both transcripts (1 melanoma cell in 10 6 peripheral blood mononuclear cells) was in line with the studies in literature (Schittek et al., 1999; Proebstle et al. 2000; Taback et al. 2001) .
Chi Square tests were used for the statistical calculations; a Kaplan-Meier analysis and logrank test were used for the survival analyses.
Results
We investigated the presence of tyrosinase and Melan A transcripts in 30 patients with malignant melanoma before and after therapy. The tyrosinase-and Melan A-specific bands in the patient samples are shown in Fig. 1 and 2 . Tyrosinase transcripts were detected in 9 of 30 patients (30%) with the metastatic disease before therapy. Five of 9 positive patients (28%) had Stage III; 4 patients (36%) had the Stage IV disease. The positivity rates for each group are given in Table  1 . Following treatment, only one patient remained positive; while no transcript was detected in the remaining patients.
Upon admission, Melan A transcripts were observed in 19 (63.3%) patients. All of the patients with the Stage IV disease were positive for Melan A transcripts. Among the patients at Stage III, 5 were positive for Melan A, 2 were positive for tyrosinase, and 3 patients were positive for both. Following therapy, Melan A was detected in 14 (46.6%) patients. Of these, 8 patients had Stage III and 6 had Stage IV disease.
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Following treatment, tyrosinase mRNA was observed in only one patient (9%). This reflects the effect of systemic therapy on circulating tumor cells. On the other hand, Melan A transcripts were still detectable in 14 (70%) patients after therapy. During the follow-up period of the disease, 9 patients (5 patients with the Stage IV disease and 4 patients with the Stage III disease) were lost by disease-related deaths. Of these, two patients were positive for Melan A on admission; one patient was positive for both markers. All of these patients had the Stage IV disease. However, this observation failed to achieve a significant association. Among the patients who were found positive for at least one of the markers on admission, 8 patients are still without relapse, while the remaining patients all had recurrences. Remarkably, among the patients in remission, three were found positive for tyrosinase on admission and turned negative following therapy. However, of the six patients who were positive for Melan A initially, only one turned negative.
The survival analysis revealed no association with PCR positivity for both transcripts.
Discussion
Routine histologic examinations are inadequate for accurately assessing the diseases spread and monitoring the progression and micrometastatic disease (Goydos et al., 1998) . A possible alternative is the use of RT-PCR to detect tumor-specific mRNA in circulation. Since subclinical metastasis may remain dormant for many years, monitoring a patients blood for circulating tumor cells may be advantageous for detecting tumor progression before clinically-evident metastases are detected. This information may be useful in identifying patients who may benefit from more intense therapies, and provide an opportunity for therapeutic intervention at an earlier stage. However, the assessment of single markers has limitations in sensitivity and specificity, based on the heterogeneity of the marker expression among tumors (Kulik et al., 2001) . Furthermore, although specific molecular techniques have been utilized for diagnostic purposes, the After Therapy III 14 --8 57 I V 6 1 9 6 1 0 0 correlation between molecular detection of circulating tumor cells and the response to therapy has not been addressed satisfactorily.
In this study, our goal was to improve the sensitivity to detect micrometastases in the circulation of melanoma patients by the simultaneous analysis of tyrosinase and Melan A transcripts. Also, we investigated to see if these markers are predictive of the therapeutic response in a clinical setting.
In our study, tyrosinase transcripts were observed in 30% of the patients. The positivity rate for tyrosinase transcripts is in accordance with literature (Foss et al., 1995; Kunter et al., 1996; Pittman et al., 1996; Jung et al., 1997; Proebstle et al., 2000) , but higher than two reports in which only a small fraction of the patients were found to have detectable numbers of cells in blood with this technique (Hoon et al., 1995; Johansson et al., 2000) . However, considerable variations in the rate of detection have also been noted (Hoon et al., 1995; Jung et al., 1997) . This may indicate that although tyrosinase transcripts are commonly found in patients with disseminated disease, they may also be absent in patients during the earlier stages of the disease (Berking et al., 1999) .
All of the patients that were positive for tyrosinase mRNA in our study had Stage III and IV of the disease. This agrees with previous studies (Brossart et al., 1995; O'Connell et al., 1998) , which reported a high sensitivity for patients with stage IV melanoma. A correlation between the presence of tyrosinase mRNA in blood and stage of the disease was reported in several studies (Mellado et al., 1996; Forthmann et al., 1998; Proebstle et al., 2000) .
Following chemotherapy, tyrosinase mRNA was found in only one of the patients. This probably reflects the effects of systemic therapy on circulating tumor cells. The continued presence of circulating cells after treatment is likely to be associated with a poor outcome. Our observations agree with reports that tyrosinase alone may not always provide a useful marker in detecting circulating melanoma cells (Hoon et al., 1995; Hasselmann et al., 2001) . This finding supports the view that the use of more than one marker is required in order to verify the presence of occult melanoma cells in peripheral blood (Hoon et al., 1995; Schittek et al., 1999a; Schittek et al., 1999b) .
Therefore, another melanocytic-lineage marker, Melan A, was included. Melan A is specifically expressed in melanocytes, melanoma cells, and in the retina (Coulie et al., 1994; Chen et al., 1996) . We observed the expression of the Melan A transcript in 63% of the patients. This ratio is consistent with an earlier report (Curry et al., 1999) , as well as the hypothesis that most melanoma tumors and cell lines express this gene (Schittek et al., 1999) . In agreement with previous reports (Kulik et al., 2001; Taback et al., 2001) , the frequency of melanoma cell detection in a patients blood was higher in our study when the two-marker assay was used. However, Melan A transcripts were still detectable in 43% of the patients following chemotherapy. This may indicate that Melan A may be more specific to the disease and not completely eradicated by chemotherapy. It has been reported that positive tyrosinase results are less frequently observed in the treated-Stage IV patients than in the untreated patients (De Vries et al., 1999) . Alternatively, it may also be due to the fact that the down-regulation of melanin synthesis is more easily achieved by treatment, while the antigen-expressing pathways may still remain functional.
Although the investigation of tyrosinase seems to better reflect the effect of systemic therapy, this may be due to the low sensitivity of tyrosinase. Reports, which suggest that tyrosinase transcripts are commonly found in disseminated disease and may be absent in earlier stages, support this notion (Glaser et al., 1997; Schittek et al., 1999) . Although it was reported that circulating-tumor cells can be detected in melanoma patients without clinical evidence of the disease (Brossart et al., 1994) , this was not the case in our study group. However, our findings are in agreement with a more recent report (Kunter et al., 1996) . We observed no association between the presence of transcripts and survival.
Our study supports the view that tyrosinase-negative samples may contain Melan A transcripts (Schittek et al., 1999) , and that the simultaneous detection of two independent markers may increase sensitivity that enables the detection of micrometastases, particularly in patients in whom the expression of one marker is down-regulated. This finding is consistent with other studies (Hoon et al., 1995; Kulik et al., 2001; Taback et al., 2001) . Since detection limits are roughly the same for both transcripts, the higher detection rate for Melan A may be associated with the characteristics of the tumor cell.
The specificity of tyrosinase and the Melan A gene expression makes this approach ideal for detecting melanoma cells in blood. We conclude that this molecular assay can provide information on the persistence of metastatic melanoma cells, and may assist in monitoring the efficacy of treatment. Further studies are needed to better assess the significance of this test in the evaluation of prognosis and early detection of relapse.
